GlassScriptPhysician profile
Robert H Grand
NPI 1831577873
$6,450.31
in general payments reported to CMS, 2019-2025
33 companies · $1,236 in 2025
The $1,236 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $1,489 · 2021: $467 · 2022: $428 · 2023: $1,648 · 2024: $705 · 2025: $1,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,590 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,589.70 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,998.71 | 2020-2024 | Da Vinci Sp |
| Boston Scientific Corporation | $953.16 | 2019-2025 | Ams 700, Spaceoar System, Spaceoar Vue System - 10ml |
| Coloplast Corp | $489.60 | 2020-2025 | Titan, Speedicath |
| Medtronic, INC. | $430.23 | 2021-2025 | Interstim, Altaviva |
| Procept Biorobotics Corporation | $379.03 | 2021-2025 | Aquabeam System, Aquabeam Robotic System |
| Teleflex LLC | $310.85 | 2021-2025 | Barrigel, Urolift |
| Urogen Pharma, INC. | $295.05 | 2022-2025 | Jelmyto |
| Axonics, INC. | $248.96 | 2021-2023 | Axonics |
| Abbvie INC. | $186.63 | 2022-2025 | |
| Astellas Pharma US INC | $152.24 | 2019-2022 | |
| Neotract INC. | $152.15 | 2019-2020 | |
| Cook Medical LLC | $116.67 | 2025 | |
| Endo Pharmaceuticals INC. | $104.53 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $72.87 | 2024-2025 | Adstiladrin |
| Janssen Biotech, INC. | $60.61 | 2023-2025 | Erleada |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $58.86 | 2025 | Orgovyx |
| Myriad Genetic Laboratories, INC. | $42.94 | 2022-2023 | Prolaris |
| Blue Earth Diagnostics | $40.22 | 2021-2022 | |
| Ethicon US, LLC | $39.56 | 2024 | Harmonic |
| Olympus America INC. | $37.07 | 2025 | Itind System |
| Palette Life Sciences, INC. | $35.92 | 2023 | |
| Ambu INC. | $34.71 | 2025 | |
| Pfizer INC. | $34.58 | 2024-2025 | |
| Innovation Technologies INC | $24.80 | 2024 | Irrisept |
| Antares Pharma, INC. | $20.78 | 2021 | |
| Photocure INC | $20.48 | 2025 | Cysview |
| Medtronic USA, INC. | $18.75 | 2020 | |
| Myovant Sciences INC. | $18.74 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $17.29 | 2021 | |
| Immunitybio, INC. | $15.40 | 2025 | |
| Coopersurgical, INC. | $14.53 | 2025 | Ally II Ups |
| Allergan, INC. | $13.47 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Grand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.